PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
43.26
-0.25 (-0.57%)
At close: 4:02PM EDT

43.20 -0.06 (-0.14%)
After hours: 6:23PM EDT

Stock chart is not supported by your current browser
Previous Close43.51
Open43.42
Bid0.00 x 21500
Ask0.00 x 1800
Day's Range42.99 - 43.68
52 Week Range33.20 - 43.68
Volume22,564,634
Avg. Volume19,596,235
Market Cap253.595B
Beta0.87
PE Ratio (TTM)11.55
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.36 (3.17%)
Ex-Dividend Date2018-08-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates
    Market Realist12 hours ago

    Pharma Stocks: Pfizer’s Revenue Trend and 2018 Estimates

    Pfizer reported a rise of 4% in its top line to ~$13.47 billion, including a 2% rise in operating revenue and a 2% favorable impact of foreign exchange, in the second quarter. Its net adjusted income rose to ~$4.8 billion in the second quarter, an 18.8% rise compared to ~$4.1 billion in the second quarter of 2017.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist15 hours ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • MarketWatchyesterday

    Health care ETF surges toward record in a broad sector rally

    The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realistyesterday

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Watson Health Still the Key Driver for IBM’s AI Business
    Market Realistyesterday

    Watson Health Still the Key Driver for IBM’s AI Business

    The growing demand for AI in the health industry has encouraged IBM (IBM) to target the health sector with its Watson Health technology. The company’s increasing presence, particularly in oncology and not only in the United States but also in highly populated countries such as China and India, is also contributing to Watson Health’s growth.

  • Exploring Pharmaceutical Stocks’ Revenue Growth Rates
    Market Realist2 days ago

    Exploring Pharmaceutical Stocks’ Revenue Growth Rates

    In this article, we’ll compare the revenue growth rates of the pharmaceutical companies under review in this series: Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?
    Zacks2 days ago

    Is the Options Market Predicting a Spike in Pfizer (PFE) Stock?

    Investors need to pay close attention to Pfizer (PFE) stock based on the movements in the options market lately.

  • Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?
    Zacks2 days ago

    Can Pfizer (PFE) Bank on Bavencio for Long-Term Growth?

    Pfizer's (PFE) latest anti-PD-L1 immunotherapy, Bavencio, is being touted as a significant long-term top-line driver for the company.

  • A Look at the Dividends Paid by Pharma Stocks in 2018
    Market Realist2 days ago

    A Look at the Dividends Paid by Pharma Stocks in 2018

    In this article, we’ll discuss the details of the dividends paid by pharmaceutical stocks Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio
    Market Realist2 days ago

    Delstrigo, Pifeltro, and Merck’s Antiviral Therapy Portfolio

    In the second quarter, Merck’s (MRK) Zepatier and Isentress reported revenues of $113.0 million and $305.0 million, respectively, which represented an ~78.0% decline and 8.0% growth on a YoY (year-over-year) basis. In the first half, Zepatier and Isentress reported net revenues of $243.0 million and $586.0 million, respectively.

  • InvestorPlace2 days ago

    Cronos Gets Bigger As It Partners With Ginkgo Bioworks

    From the looks of Cronos Group, Inc. (NASDAQ:CRON) on the charts, the stock looked like it topped around $13 and is on the way down. On Sept. 4, Cronos announced a partnership with Ginkgo Bioworks. It will produce cultured cannabinoid, the active ingredient produced in cannabis plants.

  • Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
    Zacks2 days ago

    Pfizer's Skin Disease Candidates Positive in Mid-Stage Study

    Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study.

  • A Look at the Market Caps of the Pharma Stocks under Review
    Market Realist2 days ago

    A Look at the Market Caps of the Pharma Stocks under Review

    As we discussed earlier, a few of the pharmaceutical stocks that have surpassed the returns of the S&P 500 Index YTD (year-to-date) include Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK). Let’s take a look at the details of their market caps.

  • How Pharmaceutical ETFs Have Performed in 2018
    Market Realist2 days ago

    How Pharmaceutical ETFs Have Performed in 2018

    Pharmaceutical ETFs are securities that are publicly traded on stock markets designed for investors who don’t have the capacity to hold many stocks but are interested in diversification within the pharmaceutical sector.

  • These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
    Market Realist2 days ago

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.

  • This cancer-fighting biotech sped from startup to IPO filing in 10 months
    American City Business Journals2 days ago

    This cancer-fighting biotech sped from startup to IPO filing in 10 months

    The company has raised $420 million and its experimental off-the-shelf cell therapy against cancer is in the clinic. But two deaths have been attributed to its headlining drug.

  • Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond
    Market Realist3 days ago

    Keytruda Could Boost Merck’s Revenue Growth in 2018 and Beyond

    On September 12, Merck (MRK) announced that the FDA accepted for review the company’s new supplemental Biologics License Application (or sBLA) for the label expansion of Keytruda. Merck seeks label expansion of Keytruda for approval as a monotherapy in the first-line setting. This treatment is intended for individuals with metastatic nonsquamous or squamous NSCLC (non-small cell lung cancer) with tumors expressing PD-L1 without EGFR or ALK genomic tumor abnormalities.

  • Wall Street Analysts Are Mostly Positive on Merck in September
    Market Realist5 days ago

    Wall Street Analysts Are Mostly Positive on Merck in September

    Merck (MRK) recently announced that its pivotal Phase 3 trial that evaluated Zerbaxa met its primary endpoint. Zerbaxa is an investigational antibiotic for the treatment of adult individuals with ventilated hospital-acquired bacteria pneumonia or ventilator-associated bacterial pneumonia (or VABP). Zerbaxa demonstrated non-inferiority compared to meropenem.

  • Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
    Zacks5 days ago

    Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

    Pfizer (PFE) closed at $42.97 in the latest trading session, marking a +0.34% move from the prior day.

  • How Spark Therapeutics Is Positioned in 2018
    Market Realist5 days ago

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics (ONCE) is a gene therapy company focused on developing one-time treatments that are life-altering for genetic disease patients. Spark Therapeutics has a licensing and commercialization agreement with Novartis (NVS) for its investigational voretigene neparvovec. Spark Therapeutics has two gene therapy product candidates in its pipeline: SPK-7001 and SPK-8011.

  • Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus
    Zacks5 days ago

    Pharma Stock Roundup: AZN's Leukemia Drug Wins FDA Nod, MRK's Keytruda in Focus

    Label expansion of Merck's (MRK) Keytruda and FDA approval of AstraZeneca's (AZN) leukemia drug grab headlines this week

  • Pharma/Biotech Stocks to Watch This Prostate Cancer Month
    Zacks5 days ago

    Pharma/Biotech Stocks to Watch This Prostate Cancer Month

    Here we highlight a few companies that are focused on developing treatments for prostate cancer.

  • Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal
    Zacks6 days ago

    Dow 30 Stock Roundup: Apple Unveils 3 New iPhones, Boeing Clinches $2.9B Deal

    The index chalked up gains this week amid renewed hopes of trade talks between the United States and China.

  • A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
    Motley Fool6 days ago

    A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis

    AbbVie's upadacitinib and Gilead Sciences' filgotinib could be competing for rheumatoid arthritis market share in 2020.

  • Sangamo Therapeutics: The Promise of Zinc Fingers
    Market Realist6 days ago

    Sangamo Therapeutics: The Promise of Zinc Fingers

    Sangamo Therapeutics (SGMO) is focused on developing and commercializing novel genomic therapies. Its genome editing and gene regulation platform is based on the engineering of a type of transcription factors called zinc finger DNA binding proteins (or ZFP) that naturally occur in humans. Sangamo has entered into key collaborations with Kite Pharma, a subsidiary of Gilead Sciences (GILD) and Pfizer (PFE).